查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1937774

全球妊娠毒血症診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Preeclampsia Diagnostics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 147 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

妊娠毒血症診斷市場規模預計將從 2025 年的 25 億美元成長到 2034 年的 62.2 億美元，2026 年至 2034 年的複合年成長率為 10.66%。

由於妊娠毒血症率不斷上升，以及對及時、準確診斷解決方案的需求日益成長，預計妊娠毒血症診斷市場將迎來顯著成長。子癇前症是一種妊娠相關疾病，其特徵是高血壓和器官功能障礙，對母嬰健康構成嚴重威脅。隨著醫療專業人員致力於改善孕婦的妊娠結局，能夠早期識別子癇前症的創新診斷工具的需求激增。該市場涵蓋多種產品，包括血壓計、生物標記檢測和影像技術，這些產品有助於評估子癇前症的風險。

技術進步在塑造妊娠毒血症診斷市場中發揮關鍵作用，生物標記發現和就地檢驗的創新提高了診斷能力。能夠預測妊娠毒血症發作的新型生物標記的開發正在革新產前護理方法，使醫護人員能夠採取預防措施並密切監測高風險患者。此外，遠端醫療解決方案的整合促進了對孕婦的遠距監測，確保在需要時及時介入。隨著市場的不斷發展，那些優先考慮研發以改善診斷解決方案的公司有望佔據不斷成長的市場佔有率。

此外，妊娠毒血症診斷市場日益受到監管趨勢和臨床指南的影響，這些趨勢和指南旨在促進產前護理中的實證實踐。隨著醫療系統採用標準化的妊娠毒血症診斷和管理通訊協定，對可靠、經過驗證的檢驗解決方案的需求將持續成長。這一趨勢正在推動對旨在探索新的診斷方法和改進現有技術的研究舉措的投資。隨著對母嬰健康的日益關注，對能夠根據個別患者需求量身定做的有效妊娠毒血症診斷的需求將不斷擴大，能夠根據臨床需求調整產品和服務的公司將在這個重要的市場中佔據優勢。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球妊娠毒血症診斷市場（依檢測類型分類）

  • 市場分析、洞察與預測
  • 血液檢查
  • 尿液檢查
  • 其他

5. 全球妊娠毒血症診斷市場（依產品類型分類）

  • 市場分析、洞察與預測
  • 裝置
  • 消耗品

6. 全球妊娠毒血症診斷市場（以最終用戶分類）

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 診斷中心
  • 其他

7. 全球妊娠毒血症診斷市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc
    • Siemens Healthineers
    • Abbott Laboratories
    • Beckman Coulter
    • Becton, Dickinson And Company（BD）
    • BioMAfA（C）Rieux
    • PerkinElmer
    • Quidel Corporation
    • Sera Prognostics
    • Metabolomic Diagnostics Ltd
    • Diabetomics Inc
    • Brahms GmbH
    • The Progenix Group
    • Roche Diagnostic
簡介目錄
Product Code: VMR11216696

The Preeclampsia Diagnostics Market size is expected to reach USD 6.22 Billion in 2034 from USD 2.50 Billion (2025) growing at a CAGR of 10.66% during 2026-2034.

The Preeclampsia Diagnostics market is poised for significant growth, driven by the increasing prevalence of preeclampsia and the need for timely and accurate diagnostic solutions. Preeclampsia, a pregnancy-related condition characterized by high blood pressure and organ dysfunction, poses serious risks to both maternal and fetal health. As healthcare providers seek to improve outcomes for pregnant women, the demand for innovative diagnostic tools that can identify preeclampsia early is surging. This market encompasses a range of products, including blood pressure monitors, biomarker tests, and imaging technologies that aid in the assessment of preeclampsia risk.

Technological advancements are playing a crucial role in shaping the Preeclampsia Diagnostics market, with innovations in biomarker discovery and point-of-care testing enhancing diagnostic capabilities. The development of novel biomarkers that can predict the onset of preeclampsia is revolutionizing the approach to prenatal care, enabling healthcare providers to implement preventive measures and closely monitor at-risk patients. Additionally, the integration of telehealth solutions is facilitating remote monitoring of pregnant women, ensuring timely interventions when necessary. As the market continues to evolve, companies that prioritize research and development to advance their diagnostic offerings will likely capture a larger share of the growing demand.

Furthermore, the Preeclampsia Diagnostics market is increasingly influenced by regulatory developments and clinical guidelines that promote evidence-based practices in prenatal care. As healthcare systems adopt standardized protocols for the diagnosis and management of preeclampsia, the demand for reliable and validated diagnostic solutions will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel diagnostic approaches and improving existing technologies. As the focus on maternal and fetal health grows, the need for effective preeclampsia diagnostics that can be tailored to individual patient needs will expand, positioning companies that align their offerings with clinical requirements for success in this critical market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

  • Blood Tests
  • Urine Analysis
  • Others

By Product Type

  • Instruments
  • Consumables

By End User

  • Hospital
  • Specialty Clinics
  • Diagnostic Centers
  • Others

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Thermo Fisher Scientific Inc, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company BD, bioMrieux, PerkinElmer, Quidel Corporation, Sera Prognostics, Metabolomic Diagnostics Ltd, Diabetomics Inc, Brahms GmbH, The Progenix Group, Roche Diagnostic

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Test Type
  • 4.2. Blood Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Urine Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product Type
  • 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PREECLAMPSIA DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Test Type
    • 7.2.2 By Product Type
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Test Type
    • 7.3.2 By Product Type
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Test Type
    • 7.4.2 By Product Type
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Test Type
    • 7.5.2 By Product Type
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Test Type
    • 7.6.2 By Product Type
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PREECLAMPSIA DIAGNOSTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 F. Hoffmann-La Roche Ltd
    • 9.2.2 Thermo Fisher Scientific Inc
    • 9.2.3 Siemens Healthineers
    • 9.2.4 Abbott Laboratories
    • 9.2.5 Beckman Coulter
    • 9.2.6 Becton, Dickinson And Company (BD)
    • 9.2.7 BioMAfA(C)Rieux
    • 9.2.8 PerkinElmer
    • 9.2.9 Quidel Corporation
    • 9.2.10 Sera Prognostics
    • 9.2.11 Metabolomic Diagnostics Ltd
    • 9.2.12 Diabetomics Inc
    • 9.2.13 Brahms GmbH
    • 9.2.14 The Progenix Group
    • 9.2.15 Roche Diagnostic